Abstract 153P
Background
The IMbrave150 study (Finn RS, NEJM 2020; Cheng AL, J Hepatol 2022) established atezolizumab (atezo) plus bevacizumab (bev) as the global standard of care in pts with unresectable HCC. Previously, tumour response by RECIST 1.1 was reported to be associated with OS in pts treated with atezo+bev (Ducreux M, ASCO 2021; Lim M, Hepatology 2023). Here, we report exploratory analyses investigating associations between OS and DpR or DoR.
Methods
DpR was defined as the maximum tumour shrinkage from baseline based on the sum of longest diameters as assessed by an independent review facility (IRF) per RECIST 1.1. DoR was defined as time from first documented complete or partial response by IRF assessment per RECIST 1.1 until disease progression or death, whichever occurred first. Associations between OS and DpR or DoR were evaluated by scatterplot. The Kaplan-Meier method and proportional hazard modelling were also used to estimate the survival distribution and hazard ratio (HR). The DpR analysis included pts who survived ≥6 mo to reduce immortal time bias.
Results
Of the 336 and 165 pts randomised to the atezo+bev and sorafenib arms, respectively, 264 and 99 pts who survived ≥6 mo were included in the DpR analysis, and 97 and 18 pts were included in the DoR analysis. The scatterplot of DpR-OS indicated that the association between DpR and OS was not conclusive. However, the 6-mo landmark analysis for the atezo+bev arm showed that the tumour shrinkage population (DpR <0%) had a better OS than the non-tumour shrinkage population (DpR ≥0%; HR, 0.29; 95% CI: 0.19, 0.44). A similar trend was observed for the 12-mo landmark analysis (HR, 0.31; 95% CI: 0.17, 0.55). For DoR, the scatterplot of DoR-OS showed that DoR was generally associated with OS, as expected by the definition of the endpoints. However, some pts had longer OS despite shorter DoR, and interpretation was limited due to censored pts.
Conclusions
Although these exploratory analyses have several limitations, including immortal time bias, DpR and DoR tend to be associated with OS, and tumour shrinkage may be an additional outcome measure of treatment efficacy.
Clinical trial identification
NCT03434379.
Editorial acknowledgement
Editorial assistance for this abstract was provided by Megan Zborowski of Health Interactions and funded by Chugai Pharmaceutical Co., Ltd.
Legal entity responsible for the study
F. Hoffmann-La Roche Ltd. and Chugai Pharmaceutical Co., Ltd.
Funding
F. Hoffmann-La Roche Ltd. and Chugai Pharmaceutical Co., Ltd.
Disclosure
M. Kudo: Financial Interests, Personal, Invited Speaker: Eisai, Chugai, Eli Liiy, Bayer, Takeda, AstraZeneca; Financial Interests, Institutional, Research Grant: Otsuka, EA Pharma, Taiho, Eisai, AbbVie, GE Healthcare, Chugai. T. Yamashita: Financial Interests, Personal, Speaker’s Bureau: Bayer, Chugai Pharmaceutical Co. Ltd. ; Financial Interests, Personal, Research Funding: F Hoffmann-La Roche Ltd. R.S. Finn: Financial Interests, Personal, Advisory Board: AstraZeneca, Bayer, BMS, CSTONE, Eisai, Exelixis, Eli Lilly, Merck, Pfizer, Roche, Genentech, Hengrui; Financial Interests, Personal, Invited Speaker: Pfizer, Roche, Bayer; Financial Interests, Institutional, Research Grant: Bayer, Eisai, Eli Lilly, BMS; Financial Interests, Institutional, Coordinating PI: Roche, Pfizer, Merck. P.R. Galle: Financial Interests, Personal, Sponsor/Funding: Adaptimmune, AstraZeneca, Bayer, Boston Scientific, BMS, Eisai, Eli Lilly, F. Hoffmann-La Roche Ltd, Guerbet, Ipsen, Merck, Sharp & Dohme, Sirtex Medical; Financial Interests, Personal, Other, Honoraria: Adaptimmune, AstraZeneca, Bayer, Boston Scientific, BMS, Eisai, Eli Lilly, F. Hoffmann-La Roche Ltd., Guerbet, Ipsen, Merck Sharp & Dohme, Sirtex Medical; Financial Interests, Personal, Advisory Role: Adaptimmune, AstraZeneca, Bayer, Boston Scientific, BMS, Eisai, Eli Lilly, F. Hoffmann-La Roche Ltd, Guerbet, Ipsen, Merck Sharp & Dohme, Sirtex Medical; Financial Interests, Institutional, Research Funding: F Hoffmann-La Roche Ltd, Bayer. M.P. Ducreux: Financial Interests, Personal, Advisory Role: Amgen, AstraZeneca, Bayer, Eli Lilly, F. Hoffmann-La Roche Ltd, Ipsen, Merck Serono, Pierre Fabre, Servier; Financial Interests, Personal, Other, travel: Bayer, Eli Lilly, F. Hoffmann-La Roche Ltd, Ipsen, Merck Sharp & Dohme, Servier; Financial Interests, Personal, Speaker’s Bureau: Amgen, Bayer, Eli Lilly, F Hoffmann-La Roche Ltd, Ipsen; Financial Interests, Personal, Speaker’s Bureau, F Hoffmann-La Roche Ltd: Merck Serono; Financial Interests, Institutional, Research Funding: F Hoffmann-La Roche Ltd, Bayer. A. Cheng: Financial Interests, Institutional, Research Funding: F Hoffmann-La Roche Ltd. K. Tsuchiya: Financial Interests, Personal, Advisory Role: Chugai Pharmaceutical Co. Ltd; Financial Interests, Personal, Advisory Board: Eisai; Financial Interests, Personal, Speaker’s Bureau: Chugai Pharmaceutical Co. Ltd, Eisai, Eli Lilly, Takeda; Financial Interests, Personal, Research Funding: F Hoffmann-La Roche Ltd. N. Sakamoto: Financial Interests, Personal, Financially compensated role, honoraria: AbbVie, Eisai, Gilead Sciences, Otsuka; Financial Interests, Institutional, Research Funding: Astellas Pharmaceutical, Bayer, Chugai Pharmaceutical Co., Ltd, Daiichi Sankyo, F. Hoffmann-La Roche Ltd., Gilead Sciences, Otsuka, Takeda. S. Hige: Financial Interests, Personal, Speaker, Consultant, Advisor: gilead sciences, AbbVie, Chugai Pharmaceutical Co., LTD. R. Take: Financial Interests, Personal, Full or part-time Employment: Chugai Pharmaceutical Co. Ltd.. K. Yamada: Financial Interests, Personal, Full or part-time Employment: Chugai Pharmaceutical Co. Ltd.. T. Asakawa: Financial Interests, Personal, Full or part-time Employment: Chugai Pharmaceutical Co. Ltd.. Y. Nakagawa: Financial Interests, Personal, Full or part-time Employment: Chugai Pharmaceutical Co. Ltd. M. Ikeda: Financial Interests, Personal, Financially compensated role: Bayer, Chugai Pharmaceutical Co. Ltd, Eisai, Eli Lilly, Takeda; Financial Interests, Personal, Speaker, Consultant, Advisor: Chugai Pharmaceutical Co. Ltd, Eisai; Financial Interests, Personal, Advisory Board: Eli Lilly, Merck Sharp & Dohme, Takeda; Financial Interests, Personal, Research Funding: Bayer, BMS, Chugai Pharmaceutical Co. Ltd, Eisai, Eli Lilly, F. Hoffmann-La Roche Ltd, Merck Sharp & Dohme, Takeda.
Resources from the same session
442P - Negative impact on bone homeostasis in postmenopausal women with non-metastatic breast cancer during cytotoxic chemotherapy
Presenter: Yadav Nisha
Session: Poster Display
Resources:
Abstract
443P - Efficacy of vitamin D supplementation in overall survival of cancer patients: Systematic review and meta-analysis
Presenter: Visakha Irawan
Session: Poster Display
Resources:
Abstract
444P - Commencing a nurse led symptom and urgent review clinic (SURC) in a Victorian regional cancer centre
Presenter: Sue Bartlett
Session: Poster Display
Resources:
Abstract
445P - Self-reported symptom burden, quality of life and unmet need of symptom management in nasopharyngeal cancer survivors: A cross-sectional survey
Presenter: Jerry Ching
Session: Poster Display
Resources:
Abstract
446P - A single center experience of anamorelin in patients with non-small cell lung cancer
Presenter: Takanori Ito
Session: Poster Display
Resources:
Abstract
447P - Quality of life in patients with EGFR-mutated lung cancer receiving gefitinib vs gefitinib plus pemetrexed and carboplatin chemotherapy
Presenter: Nandini Menon
Session: Poster Display
Resources:
Abstract
448P - Association of clinicopathological characteristics and pro-inflammatory markers with reduced relative dose intensity in breast cancer chemotherapy
Presenter: Susanna Hutajulu
Session: Poster Display
Resources:
Abstract
449P - Psychometric validation of the MD Anderson symptom inventory head&neck module: Chinese version in nasopharyngeal cancer survivors
Presenter: Victor Tam
Session: Poster Display
Resources:
Abstract
450P - Retrospective study of anamorelin therapy for unresectable or recurrent pancreatic cancer with cancer cachexia
Presenter: Mao Okada
Session: Poster Display
Resources:
Abstract
451P - The real-world efficacy and safety of anamorelin hydrochloride for Japanese unresectable non-small cell lung cancer patients with cachexia
Presenter: Daisuke Arai
Session: Poster Display
Resources:
Abstract